BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24582729)

  • 1. Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients.
    Nakamura R; La Rosa C; Tsai W; Lacey SF; Srivastava T; Seidel A; Senitzer D; Forman SJ; Diamond DJ
    Transpl Immunol; 2014 May; 30(4):128-35. PubMed ID: 24582729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
    Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
    Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
    Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation.
    Wölfel C; Lennerz V; Lindemann E; Hess G; Derigs HG; Huber C; Herr W; Wölfel T
    Cancer Immunol Immunother; 2008 Jun; 57(6):849-57. PubMed ID: 18004563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
    Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation.
    Goulmy E; Schipper R; Pool J; Blokland E; Falkenburg JH; Vossen J; Gratwohl A; Vogelsang GB; van Houwelingen HC; van Rood JJ
    N Engl J Med; 1996 Feb; 334(5):281-5. PubMed ID: 8532022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone.
    Eljaafari A; Yuruker O; Ferrand C; Farre A; Addey C; Tartelin ML; Thomas X; Tiberghien P; Simpson E; Rigal D; Scott D
    J Immunol; 2013 Jan; 190(1):184-94. PubMed ID: 23225889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
    Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
    Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.
    Dickinson AM; Wang XN; Sviland L; Vyth-Dreese FA; Jackson GH; Schumacher TN; Haanen JB; Mutis T; Goulmy E
    Nat Med; 2002 Apr; 8(4):410-4. PubMed ID: 11927949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-E polymorphism and clinical outcome after allogeneic hematopoietic stem cell transplantation in Egyptian patients.
    Mossallam GI; Fattah RA; El-Haddad A; Mahmoud HK
    Hum Immunol; 2015 Mar; 76(2-3):161-5. PubMed ID: 25543014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of H-Y mismatches on results of HLA-matched unrelated allogeneic hematopoietic stem cell transplantation.
    Markiewicz M; Siekiera U; Dzierzak-Mietla M; Zielinska P; Kyrcz-Krzemien S
    Transplant Proc; 2010 Oct; 42(8):3297-300. PubMed ID: 20970675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
    de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
    J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
    Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E
    Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel UTY-encoded minor histocompatibility antigen.
    Mortensen BK; Rasmussen AH; Larsen ME; Larsen MV; Lund O; Braendstrup P; Harndahl M; Rasmussen M; Buus S; Stryhn A; Vindeløv L
    Scand J Immunol; 2012 Aug; 76(2):141-50. PubMed ID: 22536994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minor histocompatibility antigens--targets of graft versus leukemia responses.
    Riddell SR; Murata M; Bryant S; Warren EH
    Int J Hematol; 2002 Aug; 76 Suppl 2():155-61. PubMed ID: 12430918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
    Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
    Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
    Ofran Y; Kim HT; Brusic V; Blake L; Mandrell M; Wu CJ; Sarantopoulos S; Bellucci R; Keskin DB; Soiffer RJ; Antin JH; Ritz J
    Clin Cancer Res; 2010 Mar; 16(5):1642-51. PubMed ID: 20160060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.